Foghorn Therapeutics Inc.
FHTX
$4.88
-$0.18-3.56%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 223.77% | 4.42% | 9.71% | 17.86% | -50.49% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 223.77% | 4.42% | 9.71% | 17.86% | -50.49% |
| Cost of Revenue | 7.50% | -18.98% | -8.43% | -15.31% | -15.27% |
| Gross Profit | 27.49% | 29.81% | 15.81% | 23.48% | 4.25% |
| SG&A Expenses | 6.99% | -4.58% | -6.32% | -6.11% | -9.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.38% | -15.81% | -7.93% | -13.17% | -13.98% |
| Operating Income | 18.37% | 22.43% | 12.94% | 18.73% | 5.71% |
| Income Before Tax | -11.08% | 17.12% | 21.95% | 24.71% | 11.83% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.08% | 17.12% | 21.95% | 24.71% | 19.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.08% | 17.12% | 21.95% | 24.71% | 19.09% |
| EBIT | 18.37% | 22.43% | 12.94% | 18.73% | 5.71% |
| EBITDA | 19.14% | 23.66% | 13.64% | 19.27% | 5.54% |
| EPS Basic | -10.74% | 17.65% | 36.07% | 49.17% | 45.66% |
| Normalized Basic EPS | 11.14% | 17.65% | 28.63% | 49.17% | 40.78% |
| EPS Diluted | -10.74% | 17.65% | 36.07% | 49.17% | 45.66% |
| Normalized Diluted EPS | 11.14% | 17.65% | 28.63% | 49.17% | 40.78% |
| Average Basic Shares Outstanding | 0.31% | 0.68% | 22.10% | 48.13% | 48.87% |
| Average Diluted Shares Outstanding | 0.31% | 0.68% | 22.10% | 48.13% | 48.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |